Is Pediatric Ulcerative Colitis Data Altering The Investment Case For Lilly (LLY)?

Eli Lilly reported one year Phase 3 SHINE-2 data showing Omvoh achieved its primary endpoint in pediatric ulcerative colitis, with 50% of Week 12 responders aged 6 to 17 in clinical remission at Week 52 and a safety profile consistent with adults. The trial enrolled a high burden group, including many children with prior biologic treatment failure. This points to a potentially meaningful extension of Eli Lilly’s inflammatory bowel disease franchise if regulators eventually approve a...